The performance of companies tied to Viagra's legacy presents a challenging investment picture . While the initial success generated substantial returns , generic copies have significantly impacted sales . Investing in associated pharmaceutical firms now requires a thorough assessment of patent protection , evolving patient changes, and the possibi